Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors

被引：5

作者：

Clark, Amy S. ^{[1
]}

Hong, Fangxin ^{[2
]}

Finn, Richard S. ^{[3
]}

DeMichele, Angela M. ^{[1
]}

Mitchell, Edith P. ^{[4
]}

Zweibel, James ^{[5
]}

Arnaldez, Fernanda I. ^{[5
]}

McShane, Lisa M. ^{[5
]}

Li, Shuli ^{[2
]}

Gray, Robert J. ^{[2
]}

Rubenstein, Larry V. ^{[5
]}

Patton, David ^{[5
]}

Williams, P. Mickey ^{[6
]}

Hamilton, Stanley R. ^{[7
]}

Copur, Mehmet S. ^{[8
]}

Kasbari, Sameer S. ^{[9
]}

Thind, Ravneet ^{[10
]}

Conley, Barbara A. ^{[5
]}

O'Dwyer, Peter J. ^{[1
]}

Harris, Lyndsay N. ^{[5
]}

Arteaga, Carlos L. ^{[11
]}

Chen, Alice P. ^{[5
]}

Flaherty, Keith T. ^{[12
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Calif Los Angeles, Los Angeles, CA USA

[4] Sidney Kimmel Canc Ctr Jefferson, Philadelphia, PA USA

[5] NCI, Bethesda, MD 20892 USA

[6] Frederick Natl Lab Canc Res, Frederick, MD USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Morrison Canc Ctr, Grand Isl, NE USA

[9] Southeastern Med Oncol Ctr, Goldboro, NC USA

[10] Univ Kentucky, Lexington, KY USA

[11] UT Southwestern Simmons Canc Ctr, San Antonio, TX USA

[12] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1158/1538-7445.AM2019-LB-010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-010

引用

页数：3